CLINIMIX N9G20E

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

LEUCINE PHENYLALANINE L-METHIONINE L-LYSINE ISOLEUCINE VALINE HISTIDINE THREONINE TRYPTOPHAN, L- ALANINE ARGININE AMINOACETIC ACID PROLINE SERINE TYROSINE SODIUM ACETATE TRIHYDRATE POTASSIUM PHOSPHATE DIBASIC SODIUM CHLORIDE MAGNESIUM CHLORIDE HEXAHYDRATE GLUCOSE CALCIUM CHLORIDE DIHYDRATE

Available from:

Baxter Healthcare Limited

Dosage:

5.5/20 %v/v

Pharmaceutical form:

Solution for Infusion

Authorization date:

1996-04-30

Summary of Product characteristics

License
IRISH MEDICINES BOARD ACTS 1995 AND 2006
MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007
(S.I. No.540 of 2007)
PA0167/098/002
Case No: 2063572
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
Baxter Healthcare Limited
Caxton Way, Thetford, Norfolk IP24 3SE, United Kingdom
an authorisation, subject to the provisions of the said Regulations, in respect of the product
CLINIMIX N9G20E, solution for infusion
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 19/05/2009 until 11/12/2009.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
Irish Medicines Board
______________________________________________________________________________________________________________________
Date Printed 19/05/2009
CRN 2063572
page number: 1
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
CLINIMIX
®
N9G20E, solution for infusion
2 QUALITATIVE AND QUANTITATIVE C